DOMIRPA TABLET 250MG [SIN17614P]
Active ingredients: BENSERAZIDE HYDROCHLORIDE EQV BENSERAZIDE | LEVODOPA
Product Info
DOMIRPA TABLET 250MG
[SIN17614P]
Product information
Active Ingredient and Strength | BENSERAZIDE HYDROCHLORIDE EQV BENSERAZIDE - 50 MG |
Dosage Form | TABLET |
Manufacturer and Country | DEVA HOLDING A.Ş. - TURKEY |
Registration Number | SIN17614P |
Licence Holder | GOLDPLUS UNIVERSAL PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | N04BA02 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
2.1 Therapeutic indications
Domirpa is indicated for the treatment of Parkinson’s disease with the exception of drug-induced Parkinsonism.
Dosing
2.2 Dosage and administration
Method of administration
Standard Domirpa tablets are breakable to facilitate swallowing.
Parkinson’s disease:
Undesirable gastrointestinal effects, which may occur mainly in the early stages of the treatment, can largely be controlled by taking Domirpa with a low protein snack [e.g. biscuits] or liquid or by increasing the dose slowly.
When possible, immediate release (Standard forms) Domirpa should be taken at least 30 minutes before or 1 hour after meals so that the competitive effect of dietary protein on levodopa uptake can be avoided (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) and to facilitate a more rapid onset of action.
Standard dosage
Treatment with Domirpa should be introduced gradually; dosage should be assessed individually and titrated for optimal effect. The following dosage instructions should therefore be regarded as guidelines.
Initial therapy
In the early stages of Parkinson’s disease it is advisable to start treatment with ½ tablet of levodopa/benseraizde ‘125’ three to four times daily. As soon as tolerability of the initial dosing schedule is confirmed, the dosage should be increased slowly in accordance with the patient’s response.
An optimal effect is generally achieved with a daily dosage of Domirpa corresponding to 300–800 mg levodopa + 75–200 mg benserazide, to be divided into 3 or more doses. Between 4 and 6 weeks may be needed to achieve the optimal effect. If it proves necessary to further increase the daily dosage, this should be done on a monthly basis.
Maintenance therapy
The average maintenance dosage is 1 tablet of levodopa/benserazide ‘125’ 3 to 6 times daily. The number of individual doses (not less than 3) and their distribution throughout the day must be titrated for optimal effect.
2.2.1. Special dosage instructions
Renal Impairment:
No dose reduction is considered necessary in case of mild or moderate renal insufficiency (see sections 2.3 Contraindications, 2.5.6 Renal Impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Hepatic Impairment:
The safety and efficacy of levodopa/benserazide have not been established in patients with hepatic impairment (see sections 2.3 Contraindications, 2.5.7 Hepatic Impairment – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Parkinson’s disease:
Dosage must be carefully titrated in all patients (see section 2.2 Dosage and Administration). Patients on other anti-parkinsonian agents may receive Domirpa. However, as treatment with Domirpa proceeds and the therapeutic effect becomes apparent, the dosage of the other drugs may need to be reduced or these drugs gradually withdrawn.
Patients who experience large fluctuations in the drug’s effect in the course of the day (on-off phenomena) should receive smaller, more frequent single doses, or be switched to levodopa/benserazide prolonged release capsules.
The switch from standard Domirpa to levodopa/benserazide prolonged release capsules is preferably made from one day to the next, beginning with the morning dose. The daily dose and dosing interval should initially be the same as with standard Domirpa.
After 2–3 days, the dosage should be gradually increased by about 50%. Patients should be informed that their condition may temporarily deteriorate.
Contraindications
2.3 Contraindications
Domirpa is contraindicated in:
patients with known hypersensitivity to levodopa or benserazide or any of the excipients.
patients receiving non-selective monoamine oxidase (MAO) inhibitors due to the risk of hypertensive crisis (see section 2.4.1 Warnings and Precautions, General – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). However, selective MAO-B inhibitors, such as selegiline and rasagiline or selective MAO-A inhibitors, such as moclobemide, are not contraindicated. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition, and hence this combination should not be given concomitantly with Domirpa (see section 2.8 Interactions with other Medicinal Products and other Forms of Interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
patients with decompensated endocrine, renal or hepatic function, cardiac disorders, psychiatric diseases with a psychotic component or closed angle glaucoma.
patients less than 25 years old (skeletal development must be complete).
pregnant women or women of childbearing potential in the absence of adequate contraception (see 2.5.2 Pregnancy and 2.5.3 Lactation – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). If pregnancy occurs in a woman taking Domirpa, the drug must be discontinued (as advised by the prescribing physician).
